Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Sanjiv Sam Gambhir
Modality
protein_peptide
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01806675CT.gov 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Giant Cell Glioblastoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| (18F)FPPRGD2 (this asset) | Sanjiv Sam Gambhir | P1/2 | CCC · 52 |
| Irinotecan | Case Comprehensive Cancer Center | P2 | BBB |
| Cediranib | Lawrence Recht | P2 | BBB |
| Temsirolimus | National Cancer Institute (NCI) | P2 | BBB |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P2 | BB |
| Sorafenib | National Cancer Institute (NCI) | P2 | BB |
| Rindopepimut | Celldex Therapeutics | P3 | BB |
| Gefitinib | National Cancer Institute (NCI) | P2 | BB |
| Vorinostat | National Cancer Institute (NCI) | P2 | BB |
+42 more in the Giant Cell Glioblastoma cohort
Other indications for (18F)FPPRGD2
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P1/2 | CCC · 55 |
| Gliosarcoma | — | P1/2 | CCC · 52 |
| Adult Glioblastoma | — | P1/2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- IrinotecanCase Comprehensive Cancer CenterBBB
- CediranibLawrence RechtBBB
- TemsirolimusNational Cancer Institute (NCI)BBB
- 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-National Cancer Institute (NCI)BB
- SorafenibNational Cancer Institute (NCI)BB
Citation
Floatz Terminal. (18F)FPPRGD2 in Giant Cell Glioblastoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/18ffpprgd2-giant-cell-glioblastoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →